| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eva Schaeffer, Ronald B Postuma, Daniela Ber. Prodromal PD: A new nosological entity. Progress in brain research. vol 252. 2021-01-11. PMID:32247370. |
this involves not only central nervous system structures outside the substantia nigra and neurotransmitter systems other than the dopaminergic system, but also the peripheral nervous systems. |
2021-01-11 |
2023-08-13 |
Not clear |
| Noela Rodriguez-Losada, Rune Wendelbob, M Carmen Ocaña, Amelia Diaz Casares, Roberto Guzman de Villoría, Jose A Aguirre Gomez, Miguel A Arraez, Pedro Gonzalez-Alegre, Miguel A Medina, Ernest Arenas, Jose A Narvae. Graphene Oxide and Reduced Derivatives, as Powder or Film Scaffolds, Differentially Promote Dopaminergic Neuron Differentiation and Survival. Frontiers in neuroscience. vol 14. 2021-01-11. PMID:33408604. |
in this study, we examined the capacity of go, full reduced (frgo), and partially reduced (prgo) powder and film to support survival, proliferation, differentiation, maturation, and bioenergetic function of a dopaminergic (da) cell line derived from the mouse substantia nigra (sn4741). |
2021-01-11 |
2023-08-13 |
mouse |
| Malk Eun Pak, Sung Min Ahn, Da Hee Jung, Hong Ju Lee, Ki Tae Ha, Hwa Kyoung Shin, Byung Tae Cho. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease. The journals of gerontology. Series A, Biological sciences and medical sciences. vol 75. issue 4. 2021-01-08. PMID:31644786. |
moreover, ea treatment induced the expression of camp response element binding protein (creb) as well as akt and pitx3 in dopaminergic neurons in the substantia nigra. |
2021-01-08 |
2023-08-13 |
mouse |
| Nami Isooka, Ikuko Miyazaki, Ryo Kikuoka, Kouichi Wada, Erika Nakayama, Kotaro Shin, Daichi Yamamoto, Yoshihisa Kitamura, Masato Asanum. Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes. Neurochemistry international. vol 132. 2021-01-07. PMID:31765686. |
subcutaneous administration of rotigotine increased mt-1,2 expression in striatal astrocytes and prevented reduction of dopaminergic neurons in the substantia nigra of a 6-ohda-lesioned mouse model of parkinson's disease. |
2021-01-07 |
2023-08-13 |
mouse |
| Christian Christensen, Haraldur Þorsteinsson, Valerie Helene Maier, Karl Ægir Karlsso. Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson's Disease in Zebrafish. Frontiers in behavioral neuroscience. vol 14. 2021-01-05. PMID:33390914. |
mpp+ selectively kills dopaminergic neurons in pars compacta of the substantia nigra, inducing parkinsonian symptoms in animals. |
2021-01-05 |
2023-08-13 |
human |
| Qi-Wen Han, Yu-He Yuan, Nai-Hong Che. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. Progress in neuro-psychopharmacology & biological psychiatry. vol 96. 2021-01-04. PMID:31442553. |
parkinson's disease (pd) is a neurodegenerative disease and its characteristic is the progressive degeneration of dopaminergic neurons within the substantia nigra (sn) of the midbrain. |
2021-01-04 |
2023-08-13 |
Not clear |
| Ifeoluwa O Awogbindin, Isaac A Adedara, Philip A Adeniyi, Alberta E Agedah, Bisola F Oyetunde, Precious D Olorunkalu, Emmanuel Ogbuewu, Inioluwa A Akindoyeni, Yusuf E Mustapha, Oluwatoyin G Ezekiel, Ebenezer O Faromb. Nigral and ventral tegmental area lesioning induces testicular and sperm morphological abnormalities in a rotenone model of Parkinson's disease. Environmental toxicology and pharmacology. vol 78. 2021-01-04. PMID:32439558. |
after 21 days of rotenone lesioning, we observed dopaminergic neuronal degeneration in the substantia nigra and hypothalamus. |
2021-01-04 |
2023-08-13 |
Not clear |
| Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Jin Tae Hong, Dong-Young Cho. Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine. Biochemical pharmacology. vol 180. 2020-12-31. PMID:32800853. |
parkinson's disease (pd) is the second most common neurodegenerative disease, which is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to a decrease in striatal dopamine. |
2020-12-31 |
2023-08-13 |
mouse |
| András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi, László Vécse. Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert opinion on pharmacotherapy. vol 21. issue 18. 2020-12-28. PMID:32808807. |
the main neuropathological cause of the disease is the death of dopaminergic neurons in the substantia nigra. |
2020-12-28 |
2023-08-13 |
Not clear |
| R Balestrino, A H V Schapir. Parkinson disease. European journal of neurology. vol 27. issue 1. 2020-12-23. PMID:31631455. |
pathologically, pd is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α-synuclein, which is found in intra-cytoplasmic inclusions called lewy bodies. |
2020-12-23 |
2023-08-13 |
Not clear |
| Maria Marsova, Elena Poluektova, Maya Odorskaya, Alexander Ambaryan, Alexander Revishchin, Galina Pavlova, Valeriy Danilenk. Protective effects of Lactobacillus fermentum U-21 against paraquat-induced oxidative stress in Caenorhabditis elegans and mouse models. World journal of microbiology & biotechnology. vol 36. issue 7. 2020-12-15. PMID:32632560. |
we assessed the state of their internal organs, the preservation of dopaminergic neurons in the substantia nigra as well as their motor coordination. |
2020-12-15 |
2023-08-13 |
mouse |
| Masayoshi Kano, Masashi Takanashi, Genko Oyama, Asako Yoritaka, Taku Hatano, Kahori Shiba-Fukushima, Makiko Nagai, Kazutoshi Nishiyama, Kazuko Hasegawa, Tsuyoshi Inoshita, Kei-Ichi Ishikawa, Wado Akamatsu, Yuzuru Imai, Silvia Bolognin, Jens Christian Schwamborn, Nobutaka Hattor. Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. NPJ Parkinson's disease. vol 6. issue 1. 2020-12-13. PMID:33298969. |
mutations in prkn cause selective dopaminergic cell loss in the substantia nigra and are presumed to induce a decrease in mitochondrial function caused by the defective clearance of mitochondria. |
2020-12-13 |
2023-08-13 |
human |
| Rita L Vaz, Diana Chapela, Joana E Coelho, Luísa V Lopes, Joaquim J Ferreira, Nuno D Afonso, Sara Sousa, Tiago F Outeir. Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia. Neuroscience. vol 424. 2020-12-10. PMID:31682948. |
the motor features in parkinson's disease (pd) are associated with the degeneration of dopaminergic cells in the substantia nigra in the brain. |
2020-12-10 |
2023-08-13 |
mouse |
| Seunghyi Kook, Xuanzhi Zhan, Kimberly Thibeault, Mohamed R Ahmed, Vsevolod V Gurevich, Eugenia V Gurevic. Mdm2 enhances ligase activity of parkin and facilitates mitophagy. Scientific reports. vol 10. issue 1. 2020-12-10. PMID:32193420. |
loss-of-function mutations in the e3 ubiquitin ligase parkin have been implicated in the death of dopaminergic neurons in the substantia nigra, which is the root cause of dopamine deficit in the striatum in parkinson's disease. |
2020-12-10 |
2023-08-13 |
Not clear |
| N V Katolikova, A B Malashicheva, R R Gainetdino. [Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice]. Molekuliarnaia biologiia. vol 54. issue 6. 2020-12-09. PMID:33276357. |
parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. |
2020-12-09 |
2023-08-13 |
Not clear |
| Kyle Farmer, Khaled S Abd-Elrahman, Alexa Derksen, Elyn M Rowe, Ashley M Thompson, Christopher A Rudyk, Natalie A Prowse, Zachary Dwyer, Samantha C Bureau, Teresa Fortin, Stephen S G Ferguson, Shawn Hayle. mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease. Molecular neurobiology. vol 57. issue 3. 2020-12-04. PMID:31754998. |
parkinson's disease is a neurodegenerative disease characterized by a loss of dopaminergic substantia nigra neurons and depletion of dopamine. |
2020-12-04 |
2023-08-13 |
mouse |
| E V Novosadova, V V Nenasheva, I V Makarova, O V Dolotov, L S Inozemtseva, E L Arsenyeva, S V Chernyshenko, R I Sultanov, S N Illarioshkin, I A Grivennikov, V Z Tarantu. Parkinson's Disease-Associated Changes in the Expression of Neurotrophic Factors and their Receptors upon Neuronal Differentiation of Human Induced Pluripotent Stem Cells. Journal of molecular neuroscience : MN. vol 70. issue 4. 2020-12-04. PMID:31820346. |
parkinson's disease (pd) is a neurodegenerative pathology resulting from the degeneration of dopaminergic (da) neurons in the substantia nigra (sn). |
2020-12-04 |
2023-08-13 |
human |
| Tomoyuki Taguchi, Masashi Ikuno, Hodaka Yamakado, Ryosuke Takahash. Animal Model for Prodromal Parkinson's Disease. International journal of molecular sciences. vol 21. issue 6. 2020-12-01. PMID:32183024. |
parkinson's disease (pd) is characterized by the loss of dopaminergic neurons in the substantia nigra and subsequent motor symptoms, but various non-motor symptoms (nms) often precede motor symptoms. |
2020-12-01 |
2023-08-13 |
Not clear |
| Tommi Kilpeläinen, Ulrika H Julku, Reinis Svarcbahs, Timo T Myöhäne. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease. Scientific reports. vol 9. issue 1. 2020-11-30. PMID:31758049. |
additionally, we found a decreased amphetamine response in locomotor activity and decreased extracellular dopaminergic markers in the striatum and substantia nigra with significantly elevated levels of asyn oligomers. |
2020-11-30 |
2023-08-13 |
mouse |
| Anup K Srivastava, Subhasree Roy Choudhury, Surajit Karmaka. Melatonin/polydopamine nanostructures for collective neuroprotection-based Parkinson's disease therapy. Biomaterials science. vol 8. issue 5. 2020-11-23. PMID:31912833. |
parkinson's disease (pd) is characterized by the loss of dopaminergic neurons in the substantia nigra and localized deposition of cytoplasmic fibrillary inclusions as lewy bodies in the brain. |
2020-11-23 |
2023-08-13 |
Not clear |